Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin–5-Fluorouracil–Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963)

REFERENCES

• Abrahamsen JF, Smaaland R, Sothern RB, Laerum OD. (1997). Circadian cell cycle variations of erythro- and myelopoiesis in humans. Eur. J. Haematol. 58:333–345.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Jordan R. (2002). Rhythms in human gastrointestinal mucosa and skin. Chronobiol. Int. 19:129–140.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Jordan RC, Sothern RB. (1999). Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am. J. Pathol. 154:613–622.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Jordan RC, Wood PA, Li Q, Lincoln DW, Sothern RB, Hrushesky WJ, Ben-David Y. (2001). Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am. J. Pathol. 158:1793–1801.
   PubMed Web of Science ®Google Scholar
• Bross ID, Rimm AA, Slack NH, Ausman RK, Jones R . (1966). Is toxicity really necessary? I. The question. Cancer 19:1780–1784.
   PubMedGoogle Scholar
• Buchi KN, Moore JG, Hrushesky WJ, Sothern RB, Rubin NH. (1991). Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 101:410–415.
   PubMed Web of Science ®Google Scholar
• Chansky K, Benedetti J, Macdonald JS. (2005). Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103:1165–1171.
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C. (2005). Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23:4866–4875.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY, Szczylik C, Clingan P, Chan RT, Tabah-Fisch I, Cassidy J. (2009). Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann. Oncol. 20:244–250.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M. (1997). Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 33:214–219.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2938–2947.
   PubMed Web of Science ®Google Scholar
• Diasio RB, Lu Z. (1994). Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J. Clin. Oncol.12:2239–2242.
   PubMed Web of Science ®Google Scholar
• Dibner C, Schibler U, Albrecht U. (2010). The Mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu. Rev. Physiol. 72:517–549.
   PubMed Web of Science ®Google Scholar
• Felici A, Verweij J, Sparreboom A. (2002). Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur. J. Cancer 38:1677–1684.
   PubMed Web of Science ®Google Scholar
• Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, Claustrat B, Hastings MH, Lévi F. (2002). Host circadian clock as a control point in tumor progression. J. Natl. Cancer Inst. 94:690–697.
   PubMed Web of Science ®Google Scholar
• Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Grechez-Cassiau A, Guettier C, Hastings MH, Lévi F. (2004). Effects of chronic jet lag on tumor progression in mice. Cancer Res. 64:7879–7885.
   PubMed Web of Science ®Google Scholar
• Filipski E, Innominato PF, Wu M, Li XM, Iacobelli S, Xian LJ, Lévi F. (2005). Effects of light and food schedules on liver and tumor molecular clocks in mice. J. Natl. Cancer Inst. 97:507–517.
   PubMed Web of Science ®Google Scholar
• Frei E 3rd, Canellos GP. (1980). Dose: a critical factor in cancer chemotherapy. Am. J. Med. 69:585–594.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M. (2008). Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 26:2099–2105.
   PubMed Web of Science ®Google Scholar
• Giacchetti S. (2002). Chronotherapy of colorectal cancer. Chronobiol. Int. 19:207–219.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:136–147
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F. (2006). Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J. Clin. Oncol. 24:3562–3569.
   PubMed Web of Science ®Google Scholar
• Granda TG, Lévi F. (2002). Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiol. Int. 19:21–41.
   PubMed Web of Science ®Google Scholar
• Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, Bissery MC, Lévi F. (2002). Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br. J. Cancer 86:999–1005.
   PubMed Web of Science ®Google Scholar
• Harris BE, Song R, Soong SJ, Diasio RB. (1990). Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:197–201.
   PubMed Web of Science ®Google Scholar
• Hrushesky WJ. (1985). Circadian timing of cancer chemotherapy. Science 228:73–75.
   PubMed Web of Science ®Google Scholar
• Hrushesky WJ, Bjarnason GA. (1993). Circadian cancer therapy. J. Clin. Oncol. 11:1403–1417.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Lévi F, Bjarnason GA. (2009). Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69:4700–4707.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Lévi FA, Bjarnason GA. (2010). Chronotherapy and the molecular clock: clinical implications in oncology. Adv. Drug Deliv. Rev. 62:979–1001.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Park JY, Kim DY, Kim JH, Kim YM, Nam JH, Kim YT. (2010). Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet. Gynecol. Scand. 89:623–628.
   PubMed Web of Science ®Google Scholar
• Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H. (2002). Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol. 13:308–317.
   PubMed Web of Science ®Google Scholar
• Kvinnsland S. (1999). The leucocyte nadir, a predictor of chemotherapy efficacy? Br. J. Cancer 80:1681.
   PubMedGoogle Scholar
• Lévi F. (2002). From circadian rhythms to cancer chronotherapeutics. Chronobiol. Int. 19:1–19.
   PubMed Web of Science ®Google Scholar
• Lévi F, Schibler U. (2007). Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47:593–628.
   PubMed Web of Science ®Google Scholar
• Lévi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathe G. (1990). Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J. Clin. Oncol. 8:705–714.
   PubMed Web of Science ®Google Scholar
• Lévi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350:681–686.
   PubMed Web of Science ®Google Scholar
• Lévi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C. (1999). A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 85:2532–2540.
   PubMed Web of Science ®Google Scholar
• Lévi F, Filipski E, Iurisci I, Li XM, Innominato P. (2007a). Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb. Symp. Quant. Biol. 72:465–475.
   PubMedGoogle Scholar
• Lévi F, Focan C, Karaboue A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. (2007b). Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv. Drug Deliv. Rev. 59:1015–1035.
   PubMed Web of Science ®Google Scholar
• Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. (2010). Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50:377–421.
   PubMed Web of Science ®Google Scholar
• Liu AC, Lewis WG, Kay SA. (2007). Mammalian circadian signaling networks and therapeutic targets. Nat. Chem. Biol. 3:630–639.
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M. (2001). High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 37:1000–1005.
   PubMed Web of Science ®Google Scholar
• Miyoshi N, Yano M, Takachi K, Kishi K, Noura S, Eguchi H, Yamada T, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Doki Y, Imaoka S. (2009). Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J. Surg. Oncol. 99:302–306.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Touitou Y, Lévi F. (2000). Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 6:3038–3045.
   PubMed Web of Science ®Google Scholar
• Paschos GK, Baggs JE, Hogenesch JB, FitzGerald GA. (2010). The role of clock genes in pharmacology. Annu. Rev. Pharmacol. Toxicol. 50:187–214.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Van Dijk J, Nadal JC, Van Groeningen CJ, Lankelma J, Pinedo HM. (1987). Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1:113–117.
   PubMedGoogle Scholar
• Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911–1929.
   PubMed Web of Science ®Google Scholar
• Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, Jasmin C, Lévi F. (2005). Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 11:1757–1764.
   PubMed Web of Science ®Google Scholar
• Sahar S, Sassone-Corsi P. (2009). Metabolism and cancer: the circadian clock connection. Nat. Rev. Cancer 9:886–896.
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. (2008). Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J. Clin. Oncol. 26:5721–5727.
   PubMed Web of Science ®Google Scholar
• Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M. (2008). Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26:2131–2138.
   PubMed Web of Science ®Google Scholar
• Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 92:994–1000.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Takahari D, Yokota T, Inaba Y, Yamaura H, Sato Y, Najima M, Ura T, Muro K. (2009). Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur. J. Cancer 45:1757–1763.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Muro K. (2011). Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother. Pharmacol. 68(2):301–307.
   PubMedGoogle Scholar
• Shitara K, Matsuo K, Takahari D, Yokota T, Shibata T, Ura T, Ito S, Sawaki A, Tajika M, Kawai H, Muro K. (2010b). Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann. Oncol. 21:2403–2409.
   PubMed Web of Science ®Google Scholar
• Smaaland R, Laerum OD, Lote K, Sletvold O, Sothern RB, Bjerknes R. (1991). DNA synthesis in human bone marrow is circadian stage dependent. Blood 77:2603–2611.
   PubMed Web of Science ®Google Scholar
• Smaaland R, Abrahamsen JF, Svardal AM, Lote K, Ueland PM. (1992a). DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br. J. Cancer 66:39–45.
   PubMed Web of Science ®Google Scholar
• Smaaland R, Laerum OD, Sothern RB, Sletvold O, Bjerknes R, Lote K. (1992b). Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood 79:2281–2287.
   PubMed Web of Science ®Google Scholar
• Smaaland R, Lote K, Sothern RB, Laerum OD. (1993). DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Cancer Res. 53:3129–3138.
   PubMed Web of Science ®Google Scholar
• Smaaland R, Sothern RB, Laerum OD, Abrahamsen JF. (2002). Rhythms in human bone marrow and blood cells. Chronobiol. Int. 19:101–127.
   PubMed Web of Science ®Google Scholar
• Takahashi JS, Hong HK, Ko CH, McDearmon EL. (2008). The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat. Rev. Genet. 9:764–775.
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. (2007). Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br. J. Cancer 97:37–42.
   PubMed Web of Science ®Google Scholar
• Yang R, Niepel M, Mitchison TK, Sorger PK. (2010). Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin. Pharmacol. Ther. 88:34–38.
   PubMedGoogle Scholar